Common Contracts
4 similar Consulting Agreement contracts by Cero Therapeutics Holdings, Inc.
CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances)
AGREEMENT, made effective this October 1st 2024 by and between CERo Therapeutics Holdings, Inc., a Delaware corporation having a place of business at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (“Company”), and Brian G. Atwood, an individual having his principal place of business at [Omitted] (“Consultant”) The Company and the Consultant are referred to herein collectively as the “Parties,” and individually, each as a “Party.” Unless the context otherwise requires, references to the “Company” shall be deemed to refer to the Company and CERo (as defined below).
CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances)
AGREEMENT, made effective this October 1st 2024 by and between CERo Therapeutics Holdings, Inc., a Delaware corporation having a place of business at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (“Company”), and Charles Ross Carter, an individual having his principal place of business at [Omitted] (“Consultant”) The Company and the Consultant are referred to herein collectively as the “Parties,” and individually, each as a “Party.” Unless the context otherwise requires, references to the “Company” shall be deemed to refer to the Company and CERo (as defined below).
CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances)
AGREEMENT, made effective this October 1st 2024 by and between CERo Therapeutics Holdings, Inc., a Delaware corporation having a place of business at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (“Company”), and Kristen Pierce, an individual having her principal address at [Omitted] (“Consultant”) The Company and the Consultant are referred to herein collectively as the “Parties,” and individually, each as a “Party.” Unless the context otherwise requires, references to the “Company” shall be deemed to refer to the Company and CERo (as defined below).
CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2024 • Cero Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances)
AGREEMENT, made effective this October 1st 2024 by and between CERo Therapeutics Holdings, Inc., a Delaware corporation having a place of business at 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (“Company”), and Andrew Albert Kucharchuk, an individual having his principal place of business at [Omitted] (“Consultant”) The Company and the Consultant are referred to herein collectively as the “Parties,” and individually, each as a “Party.” Unless the context otherwise requires, references to the “Company” shall be deemed to refer to the Company and CERo (as defined below).
